Vascular Disrupting Agents (VDA) in oncology: Advancing towards new therapeutic paradigms in the clinic

Current Drug Targets

Volumn 12, Issue 14, 2011, Pages 2009-2015

  Spear, Matthew A ^a,b,c   LoRusso, Patricia ^a,b,c   Mita, Alain ^a,b,c   Mita, Monica ^a,b,c  

^a Nereus Pharmaceuticals Inc   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c CTRC Institute for Drug Development   (United States)

Author keywords

Angiogenesis; Lung cancer; NSCLC; Tubulin; Vascular disrupting agent; Vascular targeting; VDA

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CA 4P; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; OMBRABULIN; PACLITAXEL; PLINABULIN; UNCLASSIFIED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT; VERUBULIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLEEDING; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CANCER PAIN; CANCER RISK; CELL PROLIFERATION; CELL STRUCTURE; CONNECTIVE TISSUE; CONNECTIVE TISSUE CELL; CYTOTOXICITY; DNA DAMAGE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; FATIGUE; GLIOBLASTOMA; HEART DISEASE; HEART RATE; HUMAN; ISCHEMIA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NONHUMAN; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA; SYNCOPE; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION; VISION;

ANGIOGENESIS INHIBITORS; BLOOD VESSELS; CLINICAL TRIALS AS TOPIC; DIKETOPIPERAZINES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SERINE; TUBULIN;

EID: 84855833686     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798829366     Document Type: Article

References (35)

1. Cooney MM, Heckeren W, Bhakta S. Drug insight: Vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3: 682-92.
2. Sander A, Schiller J, Gray R, et al. Restrospective evaluation of the clinical and radiographic reisk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall-cell lung cancer treated with carboplatin and pacliteaxel plus bevacizumab. J Clin Oncol 2009; 27: 1405-12.
3. Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995; 36: 143-8.
4. Corbett TH, Bissery MC, Wozniak A, et al. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 1986; 4: 207-20.
5. McKeage MJ, Fong P, Jeffery M, et al. 5,6-dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: A phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006; 12: 1776-84.
6. Gabra H, AS1404-202 Study Group Investigators. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. ASCO Annual Meeting Proceedings 2006; Part I, Vol. 24, No. 18S (June 20 Supplement): 5032.
7. Pili R, Rosenthal M, AS1404-203 study group investigators. Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study. J Clin Oncol 2008; 26: 5007.
8. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008; 99: 2006-12.
9. McKeage MJ, Reck M, Jameson MB, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/ DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009; 65(2): 192-7.
10. McKeage MJ, Jameson MB. Comparison of safety and efficacy between squaomous and non-squamous non-small cell lung cancer patients in a Phase II study of DMXAA (ASA404). J Clin Oncol 2008; 26(Suppl 15): 441s.
11. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91.
12. Scagliotti G, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIb-IV nonsmall cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, doubleblind, placebo-controlled, ESCAPE (evaluation of sorafenib, carboplatin, and paclitaxel efficacy in NSCLC) trial. Late breaking abstract presented at 1st European Lung Cancer Conference 2008.
13. ClinicalTrials. gov registry (homepage on the Internet). ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00662597
14. ClinicalTrials. gov registry (homepage on the Internet). A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer (ATTRACT-2). Available from: http://www.clinicaltrials.gov/ct2/ show/ NCT00738387
15. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumor vascular targeting agents. Int J of Exper Pathol 2002; 83: 21-38.
16. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing. Anticancer Drugs 1993; 4: 3-17.
17. Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005; 115: 2992-3006.
18. Tozer Gm, Prise VE, Wilson J et al. Combretastatin A4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59: 1626-34.
19. Neuteboom STC, Medina E, de Grandpre L, et al. NPI-2358: A novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522. EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, 2008. EJC Supplements; 2008; Vol 6(12): 450.
20. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4-phosphate as a tumor vascular targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59: 1626-34.
21. Zweifel M, Jayson G, Reed N, et al. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinumresistant ovarian cancer: Final phase II trial results. J Clin Oncol 2009; 27: 5502.
22. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008; 26(20 Suppl): 3550.
23. ClinicalTrials. gov registry (homepage on the Internet). A Study to Assess the Effectiveness of the Combination of Carboplatin, Paclitaxel, Bevacizumab and Combretastatin (CA4P) in Patients With Chemotherapy Naïve Lung Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00653939.
24. Sessa C, Lorusso P, Tolcher AW, et al. A pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Proc Amer Assoc Cancer Res 2005; 46.
25. Chebil M, Soria J, Chami L, et al. Interest of DCE-US with quantification to demonstrate the VDA effect on vascularization in patients with advanced solid tumors treated with AVE8062. J Clin Oncol 2009; 27(Suppl): e14522.
26. ClinicalTrials. gov registry (homepage on the Internet). A Study of AVE8062 in Advanced-Stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00699517
27. ClinicalTrials. gov registry (homepage on the Internet). AVE8062 in Association With Doublet Chemotherapy Cisplatin and Docetaxel in Advanced Solid Tumor. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00719524
28. Mita AC, Spear MA, Yee LK, et al. NPI-2358 (A Novel Vascular Disrupting Agent) Phase 1 Dose Escalation Trial with an RP2D Cohort. EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, 2008.
29. Heist R, Aren O, Millward M, et al. Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI-2358) combined with docetaxel in patients with non-small cell lung cancer (NSCLC). EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, 2009. Mol Cancer Ther 2009; 8(12 Suppl): C30.
30. ClinicalTrials. gov registry (homepage on the Internet). Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00630110.
31. Kurzrock R, Akerley W, Hong D, et al. ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 2007; 25(18S)(20 Suppl): 3604.
32. ClinicalTrials. gov registry (homepage on the Internet). Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00892931
33. Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. ASCO Annual Meeting Proceedings. Part I of II. J Clin Oncol 2005; 23(16S), (1 Suppl): 5009.
34. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10(6): 559-68.
35. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; Feb; 20(2): 227-30.